dc.contributorUNIC
dc.contributorUniversidade Federal de Minas Gerais (UFMG)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-12-11T17:30:37Z
dc.date.available2018-12-11T17:30:37Z
dc.date.created2018-12-11T17:30:37Z
dc.date.issued2016-11-01
dc.identifierSemina:Ciencias Agrarias, v. 37, n. 6, p. 4179-4192, 2016.
dc.identifier1679-0359
dc.identifier1676-546X
dc.identifierhttp://hdl.handle.net/11449/178490
dc.identifier10.5433/1679-0359.2016v37n6p4179
dc.identifier2-s2.0-85006298878
dc.description.abstractTendinitis is an important high-relapse-rate disease, which compromises equine performance and may result in early athletic life end to affected animals. Many therapies have been set to treat equine tendinitis; however, just few result in improved relapse rates, quality of extracellular matrix (ECM) and increased biomechanical resistance of the treated tissue. Due to advances in the regenerative medicine, promising results were initially obtained through the implantation of mesenchymal stem cells (MSC) derived from the bone marrow in the equine tendon injury. Since then, many studies have been using MSCs from different sources for therapeutic means in equine. The adipose tissue has appeared as feasible MSC source. There are promising results involving equine tendinitis therapy using mesenchymal stem cells from adipose tissue (AdMSCs).
dc.languageeng
dc.relationSemina:Ciencias Agrarias
dc.relation0,320
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectRegenerative medicine
dc.subjectStem cells
dc.subjectTendon
dc.subjectTherapy
dc.titleAdipose tissue as mesenchymal stem cells source in equine tendinitis treatment
dc.typeOtros


Este ítem pertenece a la siguiente institución